Mesothelioma Cancer Remission And Cell Research
The search for a cure to mesothelioma, the incurable asbestos-related cancer, continues as recently released figures show 2,000 diagnosed situations are recorded yearly in the UK, and the number of deaths rose to 66.4 per million people between 2006 and 2008.
The long latency period of between 15 to 50 years before the first signs of mesothelioma or asbestosis symptoms appear has often been a decisive factor in trying to detect the disease at an early stage in a bid to enhance survival rates. In addition, asbestosis treatments involving new research into genetic / cellular behaviour and drug therapy combinations have shown promising results.
Remission has been achieved in some instances, either spontaneously or by the adoption of specialised treatment procedures. While complete remission and the disappearance of all evidence of mesothelioma cancer is scarce, long-term mesothelioma survivors may be considered to be in uncompletely remission when they are able to survive for several years after diagnosis, despite the presence of the cancer tumours.
While a surgery procedure is the most likely method, which can rule to prolonging remission, uncompletely or complete remission has also been obtained from other therapies, including systemic chemotherapy, immunotherapy and oxygen therapy. In addition, the consistent application of palliative treatments, which include meaningful dietary changes by adopting a vegetarian diet plus nutritional supplements.
Recent research indicates that the nuclei of mesothelioma cells could contain vital clues for predicting patient survival, instead of a prognosis based on the prescribed stage and severity the mesothelioma has reached. examination of the nuclei of cell samples was taken from a study group of over 230 patients with malignant pleural mesothelioma.
An evaluation was then made by classification of seven calculating features, including variation in turn up, pattern of DNA and proteins, additional proteins, elements of the nucleus and abnormal division of the chromosomes.
examination of each cell sample revealed that the variation in turn up and the number of dividing cells were directly related to patient prognosis. A three-tier nuclear grade score was produced from the observations. The average patient survival for Grade I – 28 months, Grade II – 14 months, and Grade III – 5 months.
The researchers concluded, “Not only was nuclear grade an independent predictor of overall survival, but it was also a stronger discriminator of survival than all currently obtainable factors,”. In addition, the nuclear grading system also proved a useful indicator when predicting time to mesothelioma recurrence in patients who underwent complete surgical resection.